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Summary statement:  
To unlock the therapeutic potential of curcumin and related compounds, we employ a 
tractable model system to characterise their cellular and molecular effects and propose novel 
targets implicated in disease. 
 
 
Abstract: Natural compounds often have complex molecular structures and unknown 
molecular targets. These characteristics make them difficult to analyse using a classical 
pharmacological approach. Curcumin, the main curcuminoid of turmeric, is a complex 
molecule possessing wide-ranging biological activities, cellular mechanisms and roles in 
potential therapeutic treatment including Alzheimer’s disease and cancer. Here, we 
investigate the physiological effects and molecular targets of curcumin in Dictyostelium 
discoideum. We show curcumin causes acute effects on cell behaviour, reduces cell growth, 
and slows multicellular development. We then employ a range of structurally related 
compounds to show the distinct role of different structural groups cell behaviour, growth, and 
development, highlighting active moieties in cell function, and showing that these cellular 
effects are unrelated to the well-known antioxidant activity of curcumin. Molecular 
mechanisms underlying the effect of curcumin and one synthetic analogue (EF24) were then 
investigated to identify a curcumin-resistant mutant lacking the protein phosphatase 2A 
regulatory subunit (PsrA) and an EF24-resistant mutant lacking the presenilin 1 orthologue 
(PsenB). Using in-silico docking analysis, we then show that curcumin may function through 
direct binding to a key regulatory region of PsrA. These findings reveal novel cellular and 
molecular mechanisms for the function of curcumin and related compounds.  
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Introduction 
Natural products obtained from plants have been used for thousands of years as medicines 
(Butler, 2004; Newman and Cragg, 2007; Gurib-Fakim, 2006). However, the active 
compound(s) often have complicated pharmacology with multiple cellular targets and effects, 
making traditional pharmacological approaches insufficient to understand their biological 
activity. These factors preclude standard approaches to investigate mechanism(s) of action.  
Curcumin (diferuloylmethane), is a flavonoid, derived from turmeric, and provides a good 
example of a natural product with potential therapeutic activity (Aggarwal and Harikumar, 
2009; Ghosh et al., 2015). Currently, around 120 clinical trials have sought to demonstrate 
its efficacy in the treatment of various diseases (Gupta et al., 2013), yet an analysis published 
in 2017 reported that only 17 trials have shown positive outcomes (Heger, 2017). To improve 
our understanding of this compound, it is critical to identify potential therapeutic targets, and 
to test related compounds that have improved chemical characteristics (e.g. solubility) 
(Oliveira et al., 2015) that can focus research on relevant therapeutic outcomes. Curcumin 
has diverse cellular effects including the modulation of transcription and growth factors 
regulating cell growth and cell death, and as an anti- or pro-oxidant (Goel et al., 2008; Prasad 
et al., 2014; Priyadarsini, 2014; Gupta et al., 2013; Zhou et al., 2011; Gupta et al., 2012). 
Curcumin has also been extensively investigated for the treatment of Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Multiple Sclerosis (MS), cardiovascular diseases, cancer, 
allergy, asthma, rheumatoid arthritis, diabetes and inflammation (Yang et al., 2017; Lakey-
Beitia et al., 2017; Jurenka, 2009; Srinivasan, 1972; Chougala et al., 2012; Zhang et al., 
2013; Tang and Taghibiglou, 2017; McClure et al., 2017).  
The main limitations of the therapeutic use of curcumin are its poor bioavailability and limited 
understanding of the cellular effects in relation to its molecular structure (Gupta et al., 2013). 
Its structure consists of two aromatic rings containing o-methoxy phenolic groups, with a 
seven-carbon linker consisting of an α,ȕ-unsaturated ȕ-diketone (Priyadarsini, 2014; Ruby et 
al., 1995; Selvam et al., 1995). Thus modification of these group, and analysis of distinct 
cellular effects and targets may help in understanding the potential use of curcumin, and its 
derivatives in medicinal roles.  
D. discoideum has been used as a tractable model system for the analysis of compounds 
with potential therapeutic function. It is a eukaryote, with a unique lifecycle including both 
single celled and multicellular stages, and contains a range of orthologues to disease-linked 
proteins (Muller-Taubenberger et al., 2013). It has also be used to investigate the molecular 
actions of structurally and pharmacologically diverse compounds from bitter tastants 
(Cocorocchio et al., 2015; Robery et al., 2011; Robery et al., 2013), to flavonoids (Waheed 
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et al., 2014), to drugs used in the treatment of bipolar disorder (Williams et al., 2002; Williams 
et al., 1999) and epilepsy (Chang et al., 2012; Xu et al., 2007; Elphick et al., 2012; Boeckeler 
et al., 2006). Several of these studies have been successfully translated to in vitro and in vivo 
animal models (Chang et al., 2015; Chang et al., 2016; Chang et al., 2013; Chang et al., 
2014). In D. discoideum, distinct cellular processes, including growth, acute cell behaviour 
and development provide valuable tools for the analysis of compound function. Numerous 
studies using D. discoideum have employed chemical genetics approaches to identify genes 
controlling the cellular effects of compounds through screening mutant libraries to identify 
potential molecular mechanisms of compounds (Williams et al., 2002; Williams et al., 1999; 
Waheed et al., 2014; Robery et al., 2013). Several recent papers have also developed an 
approach to monitor acute effects of compounds by measuring changes in cell behaviour 
(Cocorocchio et al., 2015; Robery et al., 2011). D. discoideum is also widely used as a model 
to investigate development, where cells during starvation aggregate and differentiate to form 
multicellular fruiting bodies (Marée and Hogeweg, 2001). Thus, using D. discoideum provides 
an advantageous system to analyse the cell and molecular effects of complex natural 
products. 
In this study, we employ D. discoideum to investigate the cellular and molecular targets of 
curcumin, where previous studies have demonstrated sensitivity (Garige and Walters, 2015; 
Swatson et al., 2017). We initially corroborated the effect of curcumin on cell growth and 
development and further showed an effect on acute cell behaviour (Garige and Walters, 
2015; Swatson et al., 2017). To differentiate these cellular effects and mechanisms we then 
employ a range of complex natural and synthetic curcumin derivatives to highlight key 
functional groups of curcumin and differentiate these effects from antioxidant activity. A 
chemical genetics approach was then used to investigate molecular targets of curcumin and 
a synthetic derivative. From this approach, two proteins were identified: the protein 
phosphatase 2A regulatory subunit (psrA) gene (Lee et al., 2008) associate with cancer onset 
(Kiely and Kiely, 2015); and the presenilin 1 orthologue, PsenB (Ludtmann et al., 2014), 
implicated in Alzheimer’s disease (De Strooper and Annaert, 2010) that partially control the 
effect of these compounds. In silico modelling of curcumin binding sites was then used to 
predict a binding site on PsrA.  
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Results 
Curcumin shows distinct effects on acute cell behaviour, growth and developmental 
in D. discoideum. To investigate the cellular effects of curcumin on D. discoideum, we 
initially assessed acute cell behaviour changes following compound exposure (Fig. 1A). In 
these experiments, rapid cell movement was induced through starvation in the presence of 
pulsatile cyclic AMP (cAMP), leading to the expression of a discrete set of genes (Santhanam 
et al., 2015). Cell behaviour was recorded using time lapse microscopy for a period of 15 
minutes including pre (5 minutes) and post (10 minutes) curcumin addition (Fig. 1B), and 
computer aided cell tracking was used to analyse changes in membrane protrusions, 
normalised to average protrusions pre-treatment. From this analysis, acute cell behaviour 
was unaffected at concentrations up to 2 µM but showed a concentration-dependent 
reduction at increasing concentrations, with a complete block at 3 µM (p<0.0001****; Fig. 1B). 
By plotting average cell behaviour following treatment against curcumin concentration, a non-
linear regression analysis was used to calculate an IC50 for the effect of curcumin on acute 
cell behaviour as 2.3 M (95% CI 2.0-2.6M) (Fig. 1C). These data show an acute effect of 
curcumin on cell behaviour in D. discoideum, suggesting the presence of rapidly modified 
target(s) involved in cellular behaviour. 
We then examined the effect of curcumin treatment on D. discoideum cell growth. In these 
assays, growth was assessed in the presence of increasing concentrations of curcumin over 
seven days at concentrations ranging from 0 to 100 µM (Fig. 1D). By plotting the rate of 
exponential growth at each concentration, an IC50 value was calculated by non-linear 
regression curve fitting. Curcumin completely blocked cell growth at 100 µM with an IC50 of 
45.7 µM (95% CI 41.7-50M) (Fig. 1E). These data indicate an effect of curcumin on D. 
discoideum cell growth, suggesting cellular target(s) for the flavonoid involved in this process. 
Furthermore, the role of curcumin in regulating multicellular development was also assessed. 
When D. discoideum are starved, this causes cells to aggregate and differentiate to ultimately 
form multicellular fruiting bodies over 24 hours. The resulting fruiting body consists of a spore 
head, containing dormant spores held above the substratum by dead, vacuolated stalk cells 
(Williams et al., 2006). In this process, a further subset of proteins, partially distinct from those 
of growth and early development, are employed to enable development. In these 
experiments, cells were plated onto nutrient deficient solid media, in the absence or presence 
of curcumin at a concentration shown above to block growth, and fruiting body structure was 
recorded after 24 hours. In the absence of curcumin, a field of fruiting bodies was formed, 
with individual fruiting bodies comprising spore heads elevated by stalks (Fig 1F). In the 
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presence of curcumin (100M) cells were able to form a reduced number of aggregates and 
were unable to develop into mature fruiting bodies (Fig 1F). This suggests an effect of 
curcumin on D. discoideum late development, regulating cellular target(s) involved in 
differentiation.  
 
Identifying active moieties in curcumin responsible for distinct effects on acute cell 
behaviour, growth and development. To improve our understanding of the distinct effects 
of curcumin in D. discoideum, we employed a range of compounds structurally related to 
curcumin (both natural and synthetic) to identify structural components of the curcumin 
molecule that are necessary for distinct effects (Fig. 2A). Analysis of the curcumin-related 
compounds on acute cell behaviour was carried out as described earlier, with cell behaviour 
recorded prior to and following the addition of each compound, with data describing a loss of 
membrane protrusions post-addition (Fig. S1). Secondary plots illustrated dose dependent 
effects and provided an IC50 value specific to each compound (Fig. S2). From this approach 
(Fig. 2B), modulation of the phenolic groups through loss of one (demethoxycurcumin; DMC), 
or both methoxy groups (bisdemethoxycurcumin; BDMC), caused a step-wise reduction in 
potency in controlling acute cell behaviour (by 3.5 and 14-fold change respectively). Similarly, 
a major metabolite of curcumin, tetrahydrocucrumin (THC), lacking the α,ȕ-unsaturated 
carbonyl moiety on the seven-carbon linker leading to loss of the planar structure of the 
compound, also showed a reduced potency (5-fold change). In addition, loss of the diketone 
group through the formation of the pyrazolic ring (Jadhav et al., 2015) eliminated the effect 
on acute cell behaviour. Furthermore, FLLL31 (Yuan et al., 2014), which has two hydrogens 
on the central carbon replaced by methyl groups, and two extra methoxy groups also showed 
a reduction in potency (by 5-fold). Lastly two structurally distant compounds, EF24 and 
UBS109 were investigated, with both compounds considered to be curcumin derivatives 
(Vilekar et al., 2015; Yamaguchi et al., 2014), where EF24 showed enhanced activity (1.8-
fold), and UBS109 showed reduced activity (11-fold) in this model. These data suggest that 
the diketone moiety is essential for triggering curcumin-dependent inhibition of cell behaviour 
and that the presence of the methoxy groups and the planar nature of the molecule (lost in 
THC) and numerous changes to the basic flavonoid chemical composition in the structurally 
distant compounds provided opposite cellular effects on acute cell behaviour. 
The assessment of curcumin derivatives on D. discoideum cell growth provided insight into 
chemical moieties of curcumin necessary for this effect. Analysis was carried out as 
described earlier, with cell growth recorded over 144 hours (Fig. S3), and secondary plots to 
illustrate dose dependent effects and providing IC50 values specific to each compound (Fig. 
S4). For this cellular effect (Fig. 2C), modulation of the phenolic groups through loss of one 
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or both methoxy groups (DMC and BDMC), caused a step-wise increase in potency in 
controlling growth (by 2.5 and 14-fold change respectively). Loss of the planar nature of the 
compound (THC) also increased potency (1.8-fold change), and the addition of two methyl 
and methoxy groups in the synthetic analogue FLLL31 also increased the potency (1.5-fold). 
Loss of the diketone group through the formation of the pyrazole ring (CuPy) eliminated the 
effect on acute cell behaviour (and growth). Both structurally distinct compounds, EF24 and 
UBS109 showed a significant increase (by 14 and 26-fold change respectively) in potency in 
this model. These data suggest that the diketone moiety is essential and that the phenolic 
groups play key roles in curcumin activity in regulating cell growth.  
Development assays were also carried out to determine which structural components of 
curcumin control potency in delaying multicellular development in D. discoideum. Here, cells 
were again placed on non-nutrient agar containing curcumin derivatives at concentration that 
block growth, and allowed to develop over 24 hours, when fruiting body morphology was then 
recorded (Fig. 2D). In these studies, loss of one or both methoxy groups (DMC and BDMC), 
loss of the planar structure of the compound (THC), or substitution of the central hydrogens 
caused delayed and aberrant fruiting body morphology (FLLL31). In contrast, loss of the 
diketone group through the formation of the pyrazole ring (CuPy) eliminated the 
developmental effect, and no effect was seen for both divergent structures (UBS109 and 
EF24). These data suggest that the key moiety of curcumin involved in developmental 
regulation is the central diketone group.  
 
Analysis of antioxidant activity of curcumin-related compounds. Since curcumin has 
been widely proposed to function as an antioxidant (Sandur et al., 2007; Gordon et al., 2015) 
reducing free radicals, we then assessed this activity for curcumin and related compounds. 
Here, we employed the FRAP (ferric reducing abilities of plasma) assay, monitoring rapid 
(0min) and extended (60min) antioxidant function (Fig. 3). The strong antioxidant, ascorbic 
acid was used as a control. Of the curcumin-related compounds, THC provided the strongest 
rapid antioxidant activity, with CuPy also providing an immediate strong effect. Curcumin 
demonstrated a time-dependent antioxidant activity, increasing over the experimental period. 
Loss of one or two methoxy groups reduced this effect (DMC and BDMC), the addition of two 
methoxy groups plus two methyl groups (FLLL31), and modification of the ȕ-diketone moiety 
or major structural change (EF24 and UBS109) eliminated anti-oxidant activity (Fig. 3). 
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Identification of curcumin and analogues molecular targets using a chemical genetics 
approach. To investigate distinct molecular targets and mechanisms for these compounds, 
we employed a mutant screen using curcumin and related compounds (Table 1). In these 
experiments, a library of D. discoideum insertional mutants was grown at a concentration of 
each compound giving an 80-90% reduction in growth over 21 days. Using this approach, a 
mutant was isolated showing resistance to curcumin, with the mutagenic cassette inserted 
into the open reading frame of the protein phosphatase 2A regulatory subunit gene (psrA; 
DDB_G0280469) (Rodriguez Pino et al., 2015) (Fig. 4A). In addition, a mutant was isolated 
showing resistance to EF24, with the mutagenic cassette inserted immediately downstream 
of the start codon of the presenilin B (DDB_G0292310) (Ludtmann et al., 2014)(Fig. 4A). To 
confirm the encoded proteins regulate sensitivity to the compounds, recapitulated mutants 
were used to assess the rate of exponential growth for each mutant in the presence of the 
screening compound and a range of related structures over 24 hours (Fig. 4B, C and Fig. S5 
and S6). In the presence of curcumin, psrA- showed significant resistance compared to wild 
type cells (p<0.001), in addition to resistance to EF24 and DMC (p<0.05) (Fig. 4B). Similarly, 
in the presence of EF24, psenB- showed significant resistance compared to wild type cells 
(p<0.01), in addition to resistance to UBS109 (p<0.01), but not curcumin or BDMC (Fig. 4C).  
Since curcumin and EF24 showed effects on both growth and cell behaviour, we also 
assessed the resistance of psrA- and psenB- to the cell behaviour effects of compounds. In 
these assays, both mutants were not resistant to curcumin and related compounds (EF24 
and DMC; Fig. S7). These data highlight the distinct mechanisms of curcumin and related 
compound on growth and acute cell behaviour. 
Ligand-protein docking prediction of curcumin with psrA. Molecular docking analysis 
was used to propose an interaction site for curcumin on psrA. Here, a tertiary structure of the 
protein was based upon the mammalian orthologue, PP2A. This tertiary structure was then 
used to calculate the most stable binding site of curcumin and related compounds, showing 
the lowest energetic expenditure. This approach identified a common site, on the interface 
between the regulatory subunit B and the scaffold subunit A (based on crystallography 
studies of the human PP2A enzyme) (Cho and Xu, 2007) of the protein, that is predicted to 
bind to curcumin (deltaG -7.39), EF24 (deltaG -7.23) and DMC (deltaG -7.54), but is not 
targeted by CuPy (deltaG -6.62) (Fig. 5), consistent with resistance phenotype shown by the 
psrA- mutant. 
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Discussion 
Improving our understanding of the potential therapeutic roles of curcumin (Heger, 2017; 
Gupta et al., 2013) may facilitate its use in medicine. To do this, it is critically important to 
identify potential therapeutic targets, and to test related compounds that have improved 
chemical characteristics (e.g. solubility) (Oliveira et al., 2015) that can focus research on 
relevant therapeutic outcomes. The present study employed a novel system, the social 
amoeba D. discoideum that enables the dissection of discrete acute, growth and 
developmental effects of curcumin. Utilising curcumin-related structures identified key 
chemical moieties responsible for the effects of curcumin, and eliminated an antioxidant 
mechanism for these effects. The study then identified two novel targets related to disease 
conditions that may aid in the investigation of its role in therapeutic function. 
In this study, we initially quantified the potency of curcumin to regulate distinct aspects of 
acute cell behaviour, growth, and development in D. discoideum. We show curcumin provides 
the strongest inhibitory effect against acute cell behaviour (with an IC50 of 2.3M), with 
reduced potency against cell growth (with an IC50 of 44M) and development (>100M) (Fig. 
1). These effects support and extend a previous study (Garige and Walters, 2015), and 
provide a platform for a comparative study of related chemicals. From these combined data, 
it is likely that curcumin has more than one molecular target in D. discoideum that play distinct 
cellular roles.  
We then adopted a quantitative structure activity relationship approach (QSAR), employing 
a range of natural and artificial curcumin-related compounds to assess common and distinct 
cellular effects dependent upon the specific chemistry of the compound (Fig. 2). These 
studies showed that loss of the diketone group (in CuPy) blocked activity in all three functional 
roles (acute cell behaviour, growth and development), and modification by substitution of 
central hydrogens (FLLL31) reduced activity (in acute cell behaviour and growth) highlighting 
the key role of this group in curcumin function. For the remaining compounds, in acute cell 
behaviour, curcumin and EF24 showed the most potent activity, with any change in curcumin 
structure leading to a reduction of activity. In contrast, effects of curcumin-related compounds 
on growth showed that curcumin is the least potent of all compounds analysed. In 
development, a common delay in development was seen for the structures most related to 
curcumin, with no effect from the divergent artificial analogues (EF24 and UBS109). 
Independent of the central role of the diketone group, the remaining curcumin-related 
structure analysed here identified key regions of the chemical structure associated with 
distinct cell effects. In acute cell behaviour, the most important moieties were represented by 
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the methoxy groups and the planar structure adjacent to the diketone groups, where loss of 
one or two methoxy groups (DMC and BDMC) strongly and in incrementally reduced potency, 
and loss of the central double bonds (in THC) also reduced potency. However, the two 
synthetic analogues have a variable potency in blocking cell behaviour. A similar trend is 
present in growth inhibition but reversed, where the same molecular substitutions that 
reduced potency in acute cell behaviour enhanced potency in growth. Interestingly, curcumin 
and its closely related analogues delayed development but this was not evident for the 
synthetic analogues. These data support that curcumin has distinct targets related to acute 
cell behaviour, growth and development.  
Many of the cellular roles for curcumin have been associated with the scavenging of reactive 
oxygen species (ROS), as an antioxidant. Through the mechanism, antioxidants quench free 
radicals to inhibit cellular damage (Nimse and Pal, 2015). In this role, specific regions within 
the curcumin structure (the diketone moiety, and two phenolic groups) can undergo oxidation 
by electron transfer and hydrogen abstraction (Priyadarsini, 2014), and the methoxy groups 
of curcumin are necessary for antioxidant effects in a range of models (Yang et al., 2017). To 
investigate if the effects of curcumin and related compounds on D. discoideum were related 
to this effect, a time-dependent assay was used to assess antioxidant activity (Fig. 6). 
Surprisingly, THC and CuPy provided the largest rapid-onset activity, with both these 
compounds and curcumin providing strong activity over an extended period. The remaining 
compounds showed greatly reduced or no significant antioxidant function, consistent with a 
critical role for the diketone and methoxy groups in antioxidant function, but not supporting 
this effect in the modulation of D. discoideum acute cell behavior, growth or development 
roles. Similar outcomes for curcumin and its derivatives, shown in anti-inflammatory and 
antiproliferative effects of human-derived cancer cell lines also did not relate to their ability to 
modulate ROS (Sandur et al., 2007). Thus, in our study, we have shown that the antioxidant 
properties of curcumin and its derivatives are not related to the cellular effects in D. 
discoideum observed here, and these effects are therefore likely to occur through other 
mechanisms. 
Studies in animal models or animal derived cells provide an insight into the potential of natural 
products as therapies in humans. However, limiting research to these models precludes a 
range of experiments that may provide important step changes in investigating molecular 
mechanisms. For example, in D. discoideum, a range of novel targets for therapies and 
natural products have been proposed by using a chemical biology approach (Cocorocchio et 
al., 2015; Robery et al., 2011; Robery et al., 2013; Waheed et al., 2014; Williams et al., 2002; 
Williams et al., 1999; Chang et al., 2012; Xu et al., 2007; Elphick et al., 2012; Boeckeler et 
al., 2006). To apply this approach to curcumin and its derivatives, we identify one gene 
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product, psrA, regulating the function of curcumin, and a second gene product, presenilin B, 
regulating the function of the synthetic analogue EF24.  
The D. discoideum psrA gene encodes the orthologue of the mammalian protein 
phosphatase 2A (PP2A) regulatory subunit B56. In D. discoideum, this protein has been 
shown to regulate cell chemotaxis and differentiation by negatively modulating the glycogen 
synthase kinase 3 (GSK3) function (Rodriguez Pino et al., 2015; Lee et al., 2008). PP2A is a 
major Ser/Thr phosphatase expressed ubiquitously in eukaryotic cells. It is a heterotrimeric 
enzyme, consisting of a core dimer formed by the scaffolding subunit (A) and a catalytic 
subunit (C) (Sangodkar et al., 2016). The dimer complexes with one of the several regulatory 
subunits. In fact, there are over 80 different combinations of the PP2A holoenzyme, which 
regulates the activity and cellular localization of PP2A (Magnusdottir et al., 2009). PP2A 
regulates a wide variety of cellular processes including translation, transcription, 
inflammation, differentiation, and apoptosis (Van Hoof and Goris, 2003; Codreanu et al., 
2006). PP2A plays a pivotal role in numerous cellular processes, such as cell proliferation, 
signal transduction and apoptosis, and its deregulation is associated with multiple cancers, 
Alzheimer’s disease and increased susceptibility to pathogen infections (Cho and Xu, 2007). 
It has been shown that in many cancers, there is an abnormal function of the PP2A scaffold 
and regulatory subunits, supporting its role as a tumour suppressor (Seshacharyulu et al., 
2013; Van Hoof and Goris, 2003). In cancer treatment, data is conflicting, where patients with 
a range of cancers improve upon restoring PP2A activity (Kiely and Kiely, 2015), but 
conversely, its inhibition also leads to programmed cell death in many tumour cells. Interest 
in curcumin as an anti-cancer treatment is due to a large number of in vitro and in vivo studies 
reporting growth arrest of different types of cancer such as brain, breast, head and neck, 
liver, pancreas, colon, prostate, ovary and skin cancers (Anand et al., 2008; Kunnumakkara 
et al., 2008; Ghosh et al., 2015; Klinger and Mittal, 2016; Di Martino et al., 2017; Panda et 
al., 2017; Singh and Aggarwal, 1995; Bharti et al., 2003). In addition, curcumin has been 
demonstrated to exert neuroprotective effects by maintaining the levels of PP2A subunit B, 
leading to Tau proteins de-phosphorylation and or GSKγȕ inhibition, which prevents Tau 
hyperphosphorylation (Shah et al., 2015; Sontag and Sontag, 2014; Di Martino et al., 2016).  
In our study, we demonstrate that loss of psrA markedly reduces growth sensitivity to 
curcumin, EF24 and DMC, suggesting that these compounds may function to regulate cellular 
activity through this protein. We further propose a potential direct binding of these compounds 
to psrA through molecular docking analysis, in which these molecules bind to psrA but related 
(inactive compounds) do not. Interestingly, the region of interaction identified in this approach 
is responsible for interaction with the scaffolding subunit, which may regulate this function. 
Thus, binding of curcumin and derivatives to the PP2A core regulatory dimer may influence 
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the rate or specificity of binding to the scaffolding subunit and subsequent cellular function. 
Therefore, this approach has provided a novel insight into a mechanism of curcumin in 
regulating PP2A activity, with potential impact on therapeutic use. 
The D. discoideum presenilin B gene encodes one of two presenilin proteins, as part of the 
Ȗ-secretase complex (Ludtmann et al., 2014). Recent results in D. discoideum have shown 
that presenilin proteins play a conserved non-catalytic role which is independent its 
proteolytic activity (Otto et al., 2016b). This activity is conserved between human and D. 
discoideum proteins, since the expression of the human presenilin 1 in D. discoideum 
restores the Ȗ-secretase complex function (Ludtmann et al., 2014). In addition, it has been 
demonstrated that D. discoideum psen/Ȗ-secretase activity is required for both phagocytosis 
and cell-fate determination. Thus, presenilin function and Ȗ-secretase activity are ancient 
processes that arose prior to metazoan divergence (McMains et al., 2010). The human 
Presenilin 1 (PS1) protein, as a key component of the Ȗ -secretase complex, plays a pivotal 
role in the APP (amyloid precursor protein) cleavage to generate Aȕ, where aggregates of 
A provide a hallmark of Alzheimer’s pathology. In addition, PS1 is a substrate for GSK-γȕ, 
which is also involved in the pathology of Alzheimer’s disease (Otto et al., 2016b). Curcumin 
has been proposed to decrease Aȕ production by inhibiting GSK-γȕ-mediated PS1 activation 
(Zhang et al., 2010; Di Martino et al., 2016), and curcumin down-regulates presenilin 1 protein 
in a dose dependent manner to regulate Ȗ-secretase function (Yoshida et al., 2011). As a 
result, curcumin may have neuroprotective effects by inhibiting the generation of Aȕ and Tau 
fibrils, but the mechanisms of action remain unknown. In Alzheimer’s disease, animal models 
have shown that curcumin reduces amyloid levels and protein oxidisation that are involved 
in the cognitive decline process (Baum and Ng, 2004). Furthermore, in patients with 
Alzheimer’s disease, macrophages unable to phagocytose A show restored/enhanced 
activity following curcumin treatment (Zhang et al., 2006). Since our study identified and 
validated a mutant in lacking the presenilin B (PS1 homologue) resistant to curcumin-related 
EF24 and UBS109, these compounds may provide interesting analogues for further study in 
the treatment of Alzheimer’s disease.  
Numerous targets and effects have been proposed for curcumin that have led to its 
investigation for the treatment of several diseases. Targets include transcription and growth 
factors, cytokines, and regulators of cell growth and death (Goel et al., 2008). Furthermore, 
curcumin interacts with P-glycoprotein, glutathione, protein kinase C (PKC), ATPase, nuclear 
factor-kB, epidermal growth factor receptor (EGFR), phosphatidylinositol 3 kinase (PI3K), 
AKT, mTOR and many other cellular targets (Goel et al., 2008; Prasad et al., 2014; 
Priyadarsini, 2014; Gupta et al., 2013; Zhou et al., 2011; Gupta et al., 2012). In addition, 
several studies have examined the heptadienedione moiety, which possesses two thiol-
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reactive α,ȕ-unsaturated carbonyl groups (Fuchs et al., 2009; Ou et al., 2013), that may 
function to covalently modify cysteine residues of target proteins to regulate cellular functions. 
These results have stimulated many studies to investigate these targets and effects in a wide 
range of chronic illnesses such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Multiple Sclerosis (MS), cardiovascular diseases, cancer, allergy, asthma, rheumatoid 
arthritis, diabetes and inflammation (Yang et al., 2017; Lakey-Beitia et al., 2017; Jurenka, 
2009; Srinivasan, 1972; Chougala et al., 2012; Zhang et al., 2013; Tang and Taghibiglou, 
2017; McClure et al., 2017). It remains to be examined if the targets identified in this paper 
function as upstream modulators or downstream effectors for these curcumin-regulated 
effects. 
In this study, we demonstrated the use of a chemical biology approach to highlight active 
moieties of curcumin with cellular function using the model system D. discoideum. Based 
upon identified effects, we further employed a chemical genetics approach, to identify two 
possible molecular targets for curcumin and its derivatives, which have been associated with 
the pathogenesis of cancer and AD in animal models and patients. The study therefore 
proposes curcumin related compounds with improved chemical characteristics may provide 
beneficial therapeutic approaches to treating a range of disease that have been proposed to 
be curcumin-responsive. This approach also highlights a useful model to investigate natural 
products with multiple cellular effects and may aid in the development of new therapeutics 
related to natural products. 
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Materials and methods 
Chemicals. The following chemicals were obtained from Sigma Aldrich Co. Ltd (Dorset, UK): 
Curcumin (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; C1386), 
Demethoxycurcumin (E,E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-
heptadiene-3,5-dione; D7696), Bisdemethoxycurcumin (1E,6E)-1,7-bis(4-
hydroxyphenyl)hepta-1,6-diene-3,5-dione; B6938), EF-24 (3E,5E)-3,5-bis[(2-
fluorophenyl)methylene]-4-piperidinone; E8409), FLLL31 (E,E)-1,7-Bis(3,4-
dimethoxyphenyl)-4,4-dimethyl-1,6-heptadiene-3,5-dione; F9057), Tetrahydrocurcumin (1,7-
Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione; 50202), Adenosine γ′,5′-cyclic 
monophosphate (γ′,5′-Cyclic AMP; A9501 - 200mM stock solution). Curcumin Pyrazole ((E)-
3,5-bis[ȕ-(4-hydroxy-3-methoxyphenyl)-ethenyl]-1H-pyrazole - SL-318) was obtained from 
Syninnova. Enaminestore supplied UBS109 (3,5-Bis(2-pyridinylmethylidene)-1-methyl-4-
piperidone - Z46034963). All compounds were dissolved in dimethylsulfoxide (DMSO, 
vehicle).  
D. discoideum growth assay. D. discoideum cells were harvested and diluted in axenic 
medium to 2x104 cells/ml. Aliquots of cells (500 µl) were transferred to 24 wells plates 
containing consistent concentrations of solvent (DMSO) in addition to indicated compounds. 
Cells were grown in 24 wells plates, at 22oC, and cell density calculated over seven days. To 
provide secondary plots, a rate of exponential growth was calculated (from 72-120 hours) at 
each concentration, and normalised to control (solvent only) conditions.  
D. discoideum random cell movement and cell development. D. discoideum random cell 
movement assays, and developmental phenotypes assays were carried out as described 
(Cocorocchio et al., 2015; Robery et al., 2011). In these experiments, behaviour was 
monitored in cells undergoing random cell movement by taking images every 15 seconds 
over a 15-min period, with 5 minutes recorded prior to, and 10 minutes after compound 
addition. A minimum of three independent experiments for each drug concentration were 
used with at least 10 cells quantified per experiment. Protrusions per cell were averaged over 
the last five minutes of recording, and normalised to control (solvent only) conditions. In these 
experiments, average (untreated) protrusions per cell were around 5.7 with a maximum of 
6.4 and a minimum of 5.4, consistent with previous reports (Cocorocchio et al., 2015; Otto et 
al., 2016a). 
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D. discoideum REMI screen. To identify mutants in D. discoideum resistant to curcumin and 
analogues, two libraries of insertional mutants containing 5,000 mutants (psrA-) and 11,000 
mutants (psenB) were used. Cells were incubated with different concentrations of each 
compound over fourteen days. Mutants growing in the presence of each compound identified 
as previously described (Robery et al., 2011; Waheed et al., 2014). 
Mutant growth inhibition assay. Cells were grown in shaking suspensions and harvested 
in early exponential phase (1.5-2.5 x 106 cells/ml). Cells were then divided into aliquots and 
shaken for 24 hours in presence of solvent only or compound at a concentration which 
blocked growth by ~50% in a final volume of 2 ml axenic media. Growth (%) was defined for 
each wild type and derived mutant (Ax2 and psrA-; or Ax3 and psenB-), with growth 
normalised to relevant wild type cell growth in the absence of compound (solvent only). Each 
condition tested was carried out at least in triplicate. 
Ferric reducing ability of plasma (FRAP) assay. FRAP solution was prepared by 
combining 2 ml of TPTZ solution (10 mM 2,4,6-tripyridyl-s-triazine in 40 mM HCl), 2 ml of 
FeCl3 (10 mM) and 20 mL acetate buffer (300 mM, pH 3.6). The assay was carried out by 
combining 800 µL FRAP solution with 25 µL of positive control (1mM ascorbic acid) or 
curcumin related compounds (to give a final concentration of 31.2 µM), and the absorbance 
measured at 595 nm. Measurements were obtained in triplicates.  
Protein-ligand docking. Protein sequences were obtained from dictybase.org. The tertiary 
structure of the D. discoideum protein was predicted using Phyre2 (Protein 
Homology/analogy Recognition Engine V 2.0) (Kelley et al., 2015). Docking analysis were 
performed using SwissDock to identify the possible binding sites in psrA. UFCS Chimera was 
used to display the results obtained from SwissDock (Grosdidier et al., 2011). Results are 
expressed as delta-G (Gibbs free energy - where a negative value indicates a spontaneous 
interaction). 
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Figures 
 
 
 
Fig. 1. Acute cell behaviour, growth and developmental effects of curcumin on D. 
discoideum. (A) Curcumin, a diferuloylmethane was used to assess multiple roles using D. 
discoideum as a model. (B) Time-dependent changes in D. discoideum cell behaviour 
(membrane protrusion) were recorded over a 15-minute period (± SEM) at increasing 
concentrations of curcumin. Data is presented normalised to control conditions showing a 
significant difference between control condition (vehicle) and 3 µM (p < 0.0001 ****) using 
one-way ANOVA. (C) The concentration-dependent response is illustrated as the normalised 
reduction of cell behaviour (protrusion formation) against the Log (concentration) of curcumin, 
enabling calculation of an IC50 with a 95% confidence interval (CI). (D) D. discoideum cells 
were grown with increasing concentration of curcumin, causing a complete block at 100 µM, 
with (E) normalised concentration-dependent response shown plotted against Log curcumin 
(mM) concentration, providing an IC50 with 95% confidence interval. (F) Cells were developed 
on agar over 22 hours in presence of control conditions (vehicle) and 100 µM curcumin. Scale 
bar top view 1 mm, side view 0.25 mm. All experiments were carried out in triplicate. 
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Fig. 2. Quantification of the acute cell behaviour, growth and developmental effects of 
curcumin derivatives on D. discoideum. (A) Structure of natural and artificial derivatives 
used in a quantitative structural analysis of curcumin effects in D. discoideum. (B) 
Concentration dependent responses were determined for cell behaviour (protrusion 
formation) and illustrated as the IC50 for each compound with errors shown as 95% 
confidence intervals (Sup. Fig. 1 and 2). (C) Concentration dependent responses were 
determined for cell growth and illustrated as the IC50 for each compound with errors shown 
as 95% confidence intervals (Sup. Fig. 3 and 4). Data from B and C are presented as means 
±SEM of triplicate experiments. (D) Cells were developed on agar over 22 hours in absence 
of compounds (vehicle only), or the presence of curcumin derivatives at concentrations 
shown to block growth (100 µM FLLL31, 25 µM DMC, 20 µM BDMC, 100 µM THC, 6 µM 
EF24, 5 µM UBS109 and 100 µM Cu-Py). All images are representative of triplicate 
experiments. Scale bar top view 1 mm, side view 0.25 mm.  
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Fig. 3. Antioxidant activity of curcumin and related structures. Reducing activity was 
monitored using the ferric reducing ability of plasma (FRAP) assay. Initial rapid activity (0 
min) and sustained (60 min) activity was measured, using ascorbic acid as an antioxidant 
standard. Data are presented as means ±SEM of triplicate experiments.  
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Fig.4. Loss of psrA and psenB genes provides partial growth-resistance to curcumin 
or its derivatives. (A) Through screening, a D. discoideum mutant library, a mutant showing 
resistance to curcumin was identified showing an insertion into the protein phosphatase 2A 
regulatory subunit gene (psrA), and a mutant showing resistance to EF24 was identified 
showing an insertion into the presenilin B gene (psenB) (blue exons and black introns). (B) 
Analysis of wild type (Ax3) and recapitulated psrA- mutant growth rate confirmed that the 
psrA- mutant was resistant to curcumin, and additionally to EF24, and DMC, but not BDMC 
(Sup. Fig. 5). (C) Analysis of wild type (Ax2) and recapitulated psenB- mutant growth rate 
showed that psenB was not resistant to curcumin, was showed confirmed resistant to EF24, 
in addition to UBS109 (Sup. Fig. 6). Data are presented as means ±SEM of triplicate 
experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 
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Fig. 5. Molecular docking prediction of psrA and curcumin analogues. Tertiary protein 
structures were generated with Phyre2, with docking prediction performed by SwissDock to 
provide the most stable binding site (deltaG; Gibbs free energy). Using this approach, 
curcumin, DMC and EF24 are predicted to bind to the same site on psrA that is not shown 
for CuPy. 
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Chemical Gene ID Gene Product Orthologs Identity 
Curcumin DDB_G0281669 LMBR1 family protein Q68DH5 27 % 
 DDB_G0280469 Protein phosphatase 
2A regulatory subunit 
psrA 
Q15172 46 % 
 DDB_G0293904 NADPH-cytochrome-
P450 oxidoreductase 
ENSP00000393527 33 % 
 DDB_G0288103 Type A von Willebrand 
factor (VWFA) domain-
containing protein 
  
BDMC DDB_G0267524 Translocon-associated 
protein TRAP gamma 
subunit 
Q9UNL2 33 % 
 DDB_G0289907 EGF-like domain-
containing protein                  
C-type lectin domain-
containing protein 
  
 DDB_G0291722 UNC93-like protein 
MFSD11 
O43934-1 31 % 
 DDB_G0272684 Dihydropteridine 
reductase 
P09417 41 % 
EF24 DDB_G0276169 AAA ATPase domain-
containing protein 
Q8NBU5-1 39 % 
 DDB_G0292310 Presenilin B P49768-1 32 % 
 DDB_G0279417 LRRK family protein 
kinase Roco6 
  
UBS109 DDB_G0287861 Glycine cleavage 
system H-protein 
P23434 25 % 
 
Table 1. Genes encoding putative targets for curcumin and related compound. 
Insertions in 11 genes that were found to convey resistance to curcumin, BDMC, EF24 and 
UBS109. For each insertion, Dictybase Gene ID, product, orthologs and % identity to 
human protein have been indicated. 
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Supplementary information 
Supplementary Fig. 1. Raw data of D. discoideum acute response to curcumin derivatives. Time-
dependent changes in D. discoideum cell behaviour (membrane protrusion) were recorded over a 15 
minute period for triplicate independent experiments (± SEM) at increasing concentrations of six 
curcumin derivatives to assess their ability to inhibit protrusion formation. The addition of different 
concentration of each compound at 210 seconds caused a reduction in protrusion formation. Data is 
presented as normalised to control (vehicle) conditions. Analysis with Two-tailed t-test showed 
significant changes after the treatment with: DMC 25 µM, FLLL31 25 µM, THC 20 µM,  BDMC 40 µM, 
EF24 2.5 µM and UBS109 35 µM (p < 0.0001 ****). 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 2. Quantification of the acute effect of curcumin derivatives on D. discoideum. 
Using a range of structurally related compounds, concentration dependent responses were 
determined for D. discoideum cell behaviour (protrusion formation), and illustrated as the 
normalised reduction in response against the Log (concentration) of each compound (shown with 
errors based on the 95% confidence intervals), enabling calculation of an IC50 values and 95% 
confidence intervals for each compound.  
Supplementary Fig. 3. Raw data of D. discoideum chronic response to curcumin derivatives. D. 
discoideum cells were grown with increasing concentration of curcumin derivatives in triplicate 
independent experiments ± SEM. DMC fully blocked growth at 30 µM, FLLL31 and THC at 100 µM, 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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instead BDMC arrested growth at 20 µ, EF24 and UBS109 inhibiteg proliferation at 6 and 5 µM 
respectively.  
Supplementary Fig. 4. Quantification of the chronic effect of curcumin derivatives on D. 
discoideum. Using a range of structurally related compounds, concentration dependent responses 
were determined for D. discoideum cell growth, and illustrated as the normalised reduction in 
growth against the Log (concentration) of each compound (shown with errors based on the 95% 
confidence intervals), enabling calculation of an IC50 values and 95% confidence intervals for each 
compound.  
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 5. Growth inhibition assay - Ax3 and psrA- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psrA- mutants are resistant to curcumin as compared to 
AX2 (*** p < 0.001). psrA- mutants were also resistant to EF24 (* p < 0.05), THC (* p < 0.05) and 
DMC (** p < 0.01) in comparison to AX2. psrA- mutants were not resistant to BDMC, UBS109 and 
FLLL31. Data is provided as mean of at least three independent experiments ± SEM. 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 6. Growth inhibition assay - Ax2 and psenB- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psenB- mutants are resistant to EF24 as compared to 
AX2 (*** p < 0.001). Interestingly psenB- mutants were also resistant to UBS109 (** p < 0.01) in 
comparison to AX2. Results showed that the psenB- mutants were not resistant to curcumin, DMC, 
BDMC, THC and FLLL31. Data is provided as mean of at least three independent experiments ± SEM 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 7. Assessment of the chronic effect of curcumin and its derivatives on D. 
discoideum mutants. psenB and psrA null mutants were exposed to curcumin, DMC and EF24. The 
mean of the normalised protrusion formation was calculated for the first and the last 5 min for each 
cell line. The first set of graphs shows that the psenB- mutant is not resistant to any of the 
compounds. The second set of graphs illustrates that psrA is sensitive to this range of molecules. 
Data is provided as mean of at least three independent experiments ± SEM. 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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